Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.57 |
| ▸ | AR | P10275 | 7/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SCN1A | P35498 | 1/20 | 0.48 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.48 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9488402 | 0.84 | SLC6A3 (0.63) | MAPTARTSHRGAASMN1; SMN2 | |
| SCHEMBL27675217 | 0.83 | ALDH1A1 (0.50) | MAPTTSHRGAASMN1; SMN2CACNA1D | |
| SCHEMBL4235424 | 0.82 | MAPT (0.48) | MAPTPRKCZARRAB9AGAA | |
| SCHEMBL276323 | 0.82 | AR (0.56) | MAPTPRKCZARRAB9AGAA | |
| SCHEMBL27686802 | 0.82 | TSHR (0.65) | MAPTTSHRRAB9AGAASMN1; SMN2 | |
| SCHEMBL3230316 | 0.82 | TSHR (0.65) | MAPTTSHRGAASMN1; SMN2L3MBTL1 | |
| SCHEMBL29500171 | 0.82 | TSHR (0.65) | MAPTTSHRGAASMN1; SMN2L3MBTL1 | |
| SCHEMBL396552 | 0.82 | TSHR (0.69) | MAPTTSHRRAB9AGAASMN1; SMN2 | |
| SCHEMBL28160007 | 0.81 | TSHR (0.51) | MAPTARTSHRRAB9ASMN1; SMN2 | |
| SCHEMBL8606461 | 0.81 | TSHR (0.62) | MAPTTSHRMEN1KMT2ASCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6340772-B2 | AROMATIZATION OF CYCLOHEXENONE DERIVATIVES VIA (CHLORO)CYCLOHEXADIENE | NIPPON KAYAKU CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| US-20010020112-A1 | Process for preparing (hetero) aromatic substituted benzene derivatives | TOYA TETSUYA (JP) | 2001-09-06 | — | — | US | disclosed |
| US-6271418-B1 | AROMATIZATION OF CYCLOHEXENONE DERIVATIVES VIA (CHLORO)CYCLOHEXADIENE DERIVATIVES. | NIPPON KAYAKU CO., LTD. (JP) | 2001-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020112-A1 | Process for preparing (hetero) aromatic substituted benzene derivatives | AHR, CYP3A4, CYP4B1 | MAPT 4234/4885PRKCZ 4599/4885AR 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.